MediaPharma srl – Product Pipeline Review

Global Markets Direct’s, ‘MediaPharma srl – Product Pipeline Review – 2016’, provides an overview of the MediaPharma srl’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MediaPharma srl, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of MediaPharma srl

The report provides overview of MediaPharma srl including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses MediaPharma srl’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features MediaPharma srl’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate MediaPharma srl’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for MediaPharma srl

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding MediaPharma srl’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

MediaPharma srl Snapshot 5

MediaPharma srl Overview 5

Key Facts 5

MediaPharma srl - Research and Development Overview 6

Key Therapeutic Areas 6

MediaPharma srl - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

MediaPharma srl - Pipeline Products Glance 11

MediaPharma srl - Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

MediaPharma srl - Drug Profiles 12

MP-1959 - Drug Profile 12

Product Description 12

Mechanism Of Action 12

R&D Progress 12

MP-3546 - Drug Profile 13

Product Description 13

Mechanism Of Action 13

R&D Progress 13

MPBF-001 - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

MPE-8.3 - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

MPE-831959 - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

MPEV-20 - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

MPEV-20RT - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

MediaPharma srl - Pipeline Analysis 19

MediaPharma srl - Pipeline Products by Target 19

MediaPharma srl - Pipeline Products by Molecule Type 20

MediaPharma srl - Pipeline Products by Mechanism of Action 21

MediaPharma srl - Dormant Projects 22

MediaPharma srl - Locations And Subsidiaries 23

Head Office 23

Appendix 24

Methodology 24

Coverage 24

Secondary Research 24

Primary Research 24

Expert Panel Validation 24

Contact Us 24

Disclaimer 25

List of Tables

List of Tables

MediaPharma srl, Key Facts 5

MediaPharma srl – Pipeline by Indication, 2016 7

MediaPharma srl – Pipeline by Stage of Development, 2016 9

MediaPharma srl – Monotherapy Products in Pipeline, 2016 10

MediaPharma srl – Preclinical, 2016 11

MediaPharma srl – Pipeline by Target, 2016 19

MediaPharma srl – Pipeline by Molecule Type, 2016 20

MediaPharma srl – Pipeline Products by Mechanism of Action, 2016 21

MediaPharma srl – Dormant Developmental Projects,2016 22

List of Figures

List of Figures

MediaPharma srl – Pipeline by Top 10 Indication, 2016 7

MediaPharma srl – Pipeline by Target, 2016 19

MediaPharma srl – Pipeline by Molecule Type, 2016 20

MediaPharma srl – Pipeline Products by Mechanism of Action, 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports